Persist AI
Developing long-lasting drug formulations 50% faster
Based based in Woodland, CA, USA, Persist AI works in healthcare.
Profile
It takes 5 years for pharma to develop long lasting drug injections for chronic diseases like cancer and diabetes. Persist uses AI-driven automation to reduce formulation development time down to 2 years, a ~50% reduction.
Persist AI is positioned in healthcare, a segment that rewards a clear, focused offering.
Woodland, CA, USA is where the company is located.
Its current recorded stage is Winter 2023.
The company reports a headcount in the 6 range.
Directory analysis
Persist AI is a healthcare startup based in Woodland, CA that uses AI‑driven automation to accelerate the development of long‑lasting drug injections for chronic diseases. The company claims it can cut formulation development time from five years to about two years, a roughly 50% reduction. With a small team of six employees, Persist AI is in the Winter 2023 stage of its development.
Positioning: Persist AI targets the pharmaceutical R&D market by applying AI to formulation science, offering a potentially faster route to long‑lasting therapeutics. As an early‑stage company with a limited workforce, it remains in the proof‑of‑concept phase and its commercial impact is yet to be validated.
Note: Persist AI focuses on speeding up long‑lasting drug formulation for chronic disease treatments.
Auto-generated directory analysis from public data · updated 12 Oct 2026. Informational only, not investment advice.
| Sector | Healthcare |
|---|---|
| Headquarters | Woodland, CA, USA |
| Country | USA |
| Employees | 6 |
| Stage | Winter 2023 |
Website: www.persist-ai.com
Browse related
Create a free account